Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial

Paulo M. Hoff(Translational Research in Oncology), Brigitte Van Eyll(Apple (Israel)), Anelisa K. Coutinho(Hospital Alemão Oswaldo Cruz), Maria do Socorro Oliveira Portella(Hospital Alemão Oswaldo Cruz), Auro del Giglio(Faculdade de Medicina do ABC), Renata N. Chinen(Hospital Alemão Oswaldo Cruz), Mariangela Correa(Hospital Alemão Oswaldo Cruz), Carlos H. Barrios(Eastern Cooperative Oncology Group), Carolina Dutra(Hospital Alemão Oswaldo Cruz), Vanessa Q. Passos(Universidade de São Paulo), Nora Manoukian Forones(Federal Institute of São Paulo), Aline C Andrade(Hospital Alemão Oswaldo Cruz), Daniel Fernandes Saragiotto(Hospital Alemão Oswaldo Cruz)
Journal of Clinical Oncology
February 11, 2014
10.1200/jco.2013.50.8077
Cited by 48

Related Papers

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k